Protizinic Acid

Protizinic Acid

SCHEMBL29359535

COc1ccc2c(c1)Sc1ccc(C(C)C(=O)O)cc1N2C

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 5/20 0.54
AKR1C2 P52895 5/20 0.54
PTGS2 P35354 4/20 0.54
PTGS1 P23219 2/20 0.54
TSHR P16473 2/20 0.54
CDC42 P60953 1/20 0.54
RAC1 P63000 1/20 0.54
CYP1A2 P05177 1/20 0.54
SLC22A6 Q4U2R8 1/20 0.54
SNCA P37840 5/20 0.52
APP P05067 1/20 0.47
CYP2C19 P33261 1/20 0.47
TP53 P04637 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPK1 P28482 1/20 0.46
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.44
PKM P14618 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Protizinic Acid SCHEMBL25022 1.00 AKR1C3 (0.54) AKR1C3AKR1C2PTGS2PTGS1TSHR
Protizinic Acid SCHEMBL18309842 1.00 AKR1C3 (0.54) AKR1C3AKR1C2PTGS2PTGS1TSHR
Protizinic Acid SCHEMBL8208239 0.89 AKR1C3 (0.44) AKR1C3AKR1C2PTGS2PTGS1TSHR
SCHEMBL2739325 0.85 SNCA (0.59) PTGS1CYP1A2SNCATP53KDM4E
SCHEMBL10618628 0.82 NOX1 (0.58) AKR1C3AKR1C2PTGS2PTGS1TSHR
SCHEMBL11255517 0.82 SNCA (0.53) PTGS1CYP1A2SNCATP53KDM4E
Protizinic Acid SCHEMBL2072946 0.80 PTGS1 (0.63) AKR1C3AKR1C2PTGS2PTGS1TSHR
SCHEMBL7389154 0.77 SNCA (0.81) SNCATP53KDM4EMAPK1MAPT
SCHEMBL10941736 0.76 TP53 (0.39) PTGS2TSHRSNCATP53KDM4E
SCHEMBL2760350 0.75 SNCA (0.64) SNCATP53KDM4EMAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023023702-A1 MEDICATED SUPPLEMENT FOR ANIMALS Medical Ethics Pty Ltd (AU) 2023-03-02 WO claimed
EP-3723819-B1 WOUND DRESSING ANIMAL ETHICS PTY LTD (AU) 2026-04-22 EP disclosed
US-20260090869-A1 SYSTEMS AND DEVICES FOR THE DELIVERY OF TAILORABLE MEDICAMENT TO THE GINGIVAL CREVICE AND METHODS THEREOF 3I BIOTECH LLC (US) 2026-04-02 US disclosed
US-20250268856-A1 Pain Relieving Method ANIMAL ETHICS PTY LTD (AU) 2025-08-28 US disclosed
EP-3976018-B1 COMPOSITION FOR USE IN THE TREATMENT OF FOOT AND MOUTH DISEASE (FMD), SCABBY MOUTH (ORF), PICORNAVIRUS, PARAPOXVIRUS, AND A PATHOGENIC DISEASE CAUSING POX LESIONS ANIMAL ETHICS PTY LTD (AU) 2024-08-28 EP disclosed
US-20240091150-A1 PHARMACEUTICAL COMPOSITION COMPRISING, AS THICKENING AGENT, A COMPOSITION HAVING POLAR MEDIA THICKENING PROPERTIES SOC DEXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) 2024-03-21 US disclosed
US-20240024486-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING A POLYMER IN THE FORM OF A PULVERULENT SOLID AS THICKENING AGENT SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) 2024-01-25 US disclosed
CN-117064886-A Method for reversing normal aging process and prolonging life 麦姆德制药公司 2023-11-17 CN disclosed
EP-4274549-A1 PHARMACEUTICAL COMPOSITION COMPRISING, AS THICKENING AGENT, A COMPOSITION HAVING POLAR MEDIA THICKENING PROPERTIES Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) 2023-11-15 EP disclosed
EP-4259092-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING A POLYMER IN THE FORM OF A PULVERULENT SOLID AS THICKENING AGENT Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) 2023-10-18 EP disclosed
US-20220211620-A1 Pain Relieving Spray ANIMAL ETHICS PTY LTD (AU) 2022-07-07 US disclosed
WO-2022128453-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING A POLYMER IN THE FORM OF A PULVERULENT SOLID AS THICKENING AGENT SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) 2022-06-23 WO disclosed
US-20220193037-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING AT LEAST ONE AZOLATED LOCAL ANTIFUNGAL SUBSTANCE SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) 2022-06-23 US disclosed
US-11338055-B2 Wound dressing ANIMAL ETHICS PTY LTD 2022-05-24 US disclosed
EP-3982973-A1 PAIN RELIEVING METHOD Animal Ethics Pty Ltd (AU) 2022-04-20 EP disclosed
EP-3976018-A1 METHOD OF DISEASE CONTROL Animal Ethics Pty Ltd (AU) 2022-04-06 EP disclosed
EP-3976011-A1 PAIN RELIEVING SPRAY Animal Ethics Pty Ltd (AU) 2022-04-06 EP disclosed
CN-114040756-A Disease control method 动物伦理私人有限公司 2022-02-11 CN disclosed
US-20220031707-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING AT LEAST ONE LOCAL ANAESTHETIC SUBSTANCE SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) 2022-02-03 US disclosed
US-20220023208-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING AT LEAST ONE ANTIINFLAMMATORY SUBSTANCE SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) 2022-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220031707-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING AT LEAST ONE LOCAL ANAESTHETIC SUBSTANCE MGLL, FAAH, SGPL1 AKR1C3 482/4885AKR1C2 424/4885PTGS2 303/4885
US-20260090869-A1 SYSTEMS AND DEVICES FOR THE DELIVERY OF TAILORABLE MEDICAMENT TO THE GINGIVAL CREVICE AND METHODS THEREOF MALT1, CDH1, VEGFA AKR1C3 983/4885AKR1C2 776/4885PTGS2 2090/4885
US-20220023208-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING AT LEAST ONE ANTIINFLAMMATORY SUBSTANCE CCL11, MGLL, LIPA AKR1C3 515/4885AKR1C2 578/4885PTGS2 70/4885
US-20240024486-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING A POLYMER IN THE FORM OF A PULVERULENT SOLID AS THICKENING AGENT PGA5, SGTA, GYPA AKR1C3 1841/4885AKR1C2 2275/4885PTGS2 682/4885
US-20240091150-A1 PHARMACEUTICAL COMPOSITION COMPRISING, AS THICKENING AGENT, A COMPOSITION HAVING POLAR MEDIA THICKENING PROPERTIES PHOSPHO1, GYPA, SGTA AKR1C3 4694/4885AKR1C2 4490/4885PTGS2 1371/4885
US-20220193037-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING AT LEAST ONE AZOLATED LOCAL ANTIFUNGAL SUBSTANCE ERG28, UGCG, DEGS1 AKR1C3 51/4885AKR1C2 93/4885PTGS2 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.